Zai Lab Limited American Depositary Shares (NASDAQ:ZLAB) and argenx SE (NASDAQ:ARGX) announced positive topline results on August 17 from their Phase 3 ALKIVIA study evaluating VYVGART Hytrulo in adults with autoimmune myositis. In the combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) population, patients treated with efgartigimod achieved a statistically significant, 15.4-point greater improvement in […]

European equities traded in the US as American depositary receipts were tracking higher late Wednesd

argenx's shares jump 16% as Vyvgart Hytrulo delivered positive phase III ALKIVIA data, supporting its potential label expansion in autoimmune myositis.

Argenx's (ARGX) latest myositis data strengthened the outlook for efgartigimod, particularly in immu

argenx recently reported that its ALKIVIA Phase 3 trial of VYVGART Hytrulo in adults with autoimmune myositis met its primary endpoint, with patients showing statistically significant and clinically meaningful improvements in Total Improvement Score over 52 weeks versus placebo and a safety profile consistent with prior studies. A key insight is that this is the first Phase 3 study to show such benefit in immune-mediated necrotizing myopathy, a subtype with no approved targeted therapies,...

Argenx’s success in recent years was driven by Vyvgart. New trial data indicates the drug’s use could be expanded into treating other conditions.

Healthcare stocks were mixed Monday afternoon, with the NYSE Healthcare Index up nearly 0.1% and the

Argenx’s Vyvgart Hytrulo could provide IMNM autoimmune myositis patients a treatment option.

European equities traded in the US as American depositary receipts started the week tracking modestl

argenx (NASDAQ:ARGX) reported positive topline results from its Phase 3 ALKIVIA trial of VYVGART Hytrulo in adults with autoimmune myositis, with the study meeting its primary endpoint in the combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) population. The Phase 3 ALKIVIA trial produced a statistically significant 15.

argenx (NASDAQ:ARGX) reported positive top-line results from its Phase III ALKIVIA trial of VYVGART Hytrulo in autoimmune myositis, meeting its primary endpoint in a combined population of patients with immune-mediated necrotizing myopathy, or IMNM, and dermatomyositis, or DM. The study evaluated e

Argenx stock surged Monday after its blockbuster autoimmune drug, Vyvgart, showed promise in patients with inflammatory diseases.

The latest results give investors confidence in the drug's ability to be approved in another indication for which there are no approved treatments.

European markets started the new week mostly higher with the Europe-wide Stoxx 600 index gaining and boosted by technology and pharma stocks.

European equities traded in the US as American depositary receipts were tracking lower late Friday m

argenx SE (NASDAQ:ARGX) agreed to buy Forte Biosciences, Inc. (NASDAQ:FBRX) for about $2.2 billion in cash, paying $77 a share, a roughly 40% premium to Forte’s Friday closing price. The deal adds Forte’s experimental drug FB102, which analysts describe as a first-in-class anti-CD122 antibody, to Argenx’s immunology pipeline. Both companies’ boards have approved the deal, […]

Recent share performance and business profile Without a single clear news event driving headlines, argenx (ENXTBR:ARGX) has still drawn attention after a recent move in its share price and steady gains over the past year. The stock last closed at €767, with returns around 0.5% over the past day and roughly 6% over the past week. Over the past month the move has been closer to flat, while the past 3 months show a gain of about 9.9%. On a year to date basis the stock is up about 6%, and the 1...

argenx stock has delivered a strong long term return over the past five years, yet the current valuation checks and recent acquisition plans raise questions about how much optimism is already reflected in the price. argenx has returned 193.8% over the past five years, which puts extra focus on whether recent gains are backed by enduring fundamentals rather than just momentum. The tender offer to acquire Forte Biosciences may support growth expectations if integration goes well. At the same...

argenx (ENXTBR:ARGX) is set to consider and discuss the acquisition of Forte Biosciences, Inc. The potential deal would expand argenx's reach in biopharmaceutical research and development. Management attention on the proposed acquisition could influence argenx's capital allocation priorities. Investors are watching for details on valuation terms and integration plans once disclosed. This kind of transaction is one part of a broader opportunity set in biopharma and beyond, so it can be...

AbCellera Biologics (NASDAQ:ABCL) reported top-line four-week results from a Phase II trial of ABCL-635, an investigational non-hormonal treatment for moderate to severe vasomotor symptoms, or hot flashes, associated with menopause. The randomized, double-blind, placebo-controlled study enrolled 92

HALO's Q2 earnings and revenues surpass estimates, fueled by higher royalties and product sales. The company raises its 2026 outlook.

OmniAb raises full-year guidance to $32M-$36M, driven by milestone achievements and growing partner momentum.

European equities traded in the US as American depositary receipts were edging higher late Wednesday

Argenx (ARGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]

European equities traded in the US as American depositary receipts started the week off lower late M